Antivascular therapy of cancer: DMXAA

摘要: The vascular endothelium of tumour tissue, which differs in several ways from that normal tissues, is a potential target for selective anticancer therapy. By contrast with antiangiogenic agents, antivascular agents the endothelial cells existing blood vessels, causing distortion or damage and consequently decreasing flow. DMXAA (5,6-dimethylxanthenone-4-acetic acid), low-molecular-weight drug, has striking some cases curative effect experimental tumours. Its action on seems to involve cascade events leading induction haemorrhagic necrosis. These include both direct indirect effects, latter involving release further vasoactive such as serotonin, necrosis factor, other cytokines, nitric oxide host cells. Phase I clinical trials have been completed next challenge face how this drug should be exploited treatment human cancer.